No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Fresenius & Celltrion Secure US Interchangeability for Denosumab Biosimilars
The FDA has approved denosumab biosimilars Conexxence® and Bomyntra® (Fresenius Kabi) and Stobocolo® and Osenvelt® (Celltrion) as interchangeable with Amgen’s Prolia® and Xgeva®, respectively, for all approved indications, effective as of 29 October 2025.